Want to see FTH full AI Analyst Report?

Faeth Therapeutics (FTH) Price & Analysis

243 Followers

FTH Stock Chart & Stats

$11.42

-$0.03(-5.03%)

At close: Jan 08 4:00 PM EST

$11.42

-$0.03(-5.03%)

Day’s Range― - ―

52-Week Range$6.33 - $36.93

Previous CloseN/A

VolumeN/A

Average Volume (3M)38.93K

Market Cap

$932.16M

Enterprise Value-$128.96M

Total Cash (Recent Filing)$202.79M

Total Debt (Recent Filing)$1.04M

Price to Earnings (P/E)―

Beta1.77

Next Earnings

Aug 11, 2026

EPS Estimate

-3.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-147.90

Shares Outstanding25,778,753

10 Day Avg. Volume109,584

30 Day Avg. Volume38,927

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.72

Price to Sales (P/S)0.00

P/FCF Ratio-0.66

Enterprise Value/Market Cap-0.14

Enterprise Value/Revenue26.58

Enterprise Value/Gross Profit0.97

Enterprise Value/Ebitda0.70

Forecast

1Y Price Target

$55.40

Price Target Upside385.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-118.07

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Tumor-metabolism FocusFaeth’s strategic focus on therapies that exploit tumor metabolism targets a structural niche in oncology. This differentiated scientific angle supports durable partnership potential, combination therapy strategies, and distinct IP pathways, which can drive long-term clinical and commercial optionality if R&D advances succeed.

Low LeverageA low debt burden reduces near-term solvency risk and preserves flexibility for a capital-intensive clinical development path. With limited interest obligations, management can prioritize R&D and strategic options rather than servicing debt, extending runway options until successful program milestones or financing events occur.

Capital Access & Simplified StructureEstablishing an at-the-market equity program and converting preferred shares materially changes financing flexibility and float. The ATM is a persistent financing tool enabling opportunistic raises, while conversion simplifies the cap table and can improve common-share liquidity—both structural improvements for funding options and market depth.

Bears Say

No Revenue BaseFaeth lacks operating revenues, leaving it entirely dependent on external financing and R&D success to create value. Absence of product sales lengthens time to self-sustaining cash generation, increases execution risk, and makes long-term planning contingent on successful trials or partnerships rather than internal cash flows.

Sustained Cash BurnPersistent negative operating and free cash flow indicate ongoing burn to support R&D and operations. Even with some year-over-year improvement, TTM outflows remain substantial, raising the probability of frequent financings, which can dilute shareholders and complicate multi-year program continuity absent milestone-driven funding.

Negative Shareholders' EquityNegative stockholders’ equity is a durable red flag reflecting accumulated losses that impair financial flexibility. It can restrict borrowing capacity, increase cost of capital, and lead to more dilutive or onerous financing structures, making sustained investment into late-stage development and commercialization more challenging.

Faeth Therapeutics News

Faeth Therapeutics initiated with an Outperform at Baird

Baird analyst Jack Allen initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $57 price target...

17d ago

FTH

Faeth Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $60 price target The firm...

20d ago

FTH

Faeth Therapeutics files automatic mixed securities shelf

16:03 EDT Faeth Therapeutics (FTH) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

24d ago

FTH

Faeth’s PIKTOR Trial Targets Advanced Breast Cancer With a New Combo Approach

Faeth Therapeutics, Inc. ($FTH) announced an update on their ongoing clinical study. Faeth Therapeutics, Inc. is running an...

10d ago

FTH

FTH FAQ

What was Faeth Therapeutics’s price range in the past 12 months?

Faeth Therapeutics lowest stock price was $6.33 and its highest was $36.93 in the past 12 months.

What is Faeth Therapeutics’s market cap?

Faeth Therapeutics’s market cap is $932.16M.

When is Faeth Therapeutics’s upcoming earnings report date?

Faeth Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 30 days.

How were Faeth Therapeutics’s earnings last quarter?

Faeth Therapeutics released its earnings results on May 15, 2026. The company reported -$131.45 earnings per share for the quarter, missing the consensus estimate of -$0.62 by -$130.83.

Is Faeth Therapeutics overvalued?

According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Faeth Therapeutics pay dividends?

Faeth Therapeutics does not currently pay dividends.

What is Faeth Therapeutics’s EPS estimate?

Faeth Therapeutics’s EPS estimate is -3.55.

How many shares outstanding does Faeth Therapeutics have?

Faeth Therapeutics has 25,778,753 shares outstanding.

What happened to Faeth Therapeutics’s price movement after its last earnings report?

Faeth Therapeutics reported an EPS of -$131.45 in its last earnings report, missing expectations of -$0.62. Following the earnings report the stock price went up 3.078%.

Which hedge fund is a major shareholder of Faeth Therapeutics?

Currently, no hedge funds are holding shares in FTH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Faeth Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-283.67%

Trailing 12-Months

Asset Growth

436.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Faeth Therapeutics

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Faeth Therapeutics (FTH) Earnings & Revenues

Historic Earnings Reports

FTH Stock 12 Month Forecast

Average Price Target

$55.40

▲(385.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","61":"$61","19.75":"$19.75","33.5":"$33.5","47.25":"$47.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,19.75,33.5,47.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.66,26.455384615384617,29.25076923076923,32.04615384615384,34.84153846153846,37.63692307692308,40.43230769230769,43.22769230769231,46.02307692307693,48.81846153846154,51.613846153846154,54.409230769230774,57.20461538461538,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.66,26.10153846153846,28.543076923076924,30.984615384615385,33.426153846153845,35.86769230769231,38.309230769230766,40.75076923076923,43.19230769230769,45.63384615384615,48.07538461538461,50.51692307692308,52.958461538461535,{"y":55.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.66,25.686153846153847,27.712307692307693,29.738461538461536,31.764615384615382,33.79076923076923,35.816923076923075,37.84307692307692,39.86923076923077,41.895384615384614,43.92153846153846,45.94769230769231,47.973846153846154,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.325,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.67,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.81,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.79,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26.96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >